Although the clinical research disclosed that STING agonist ADU-S100 might induce CD8+ T cell immune response at a low dose, when administered at a high dose, the CD8+ T cell death, and compromised anti-tumor immunity (Sivick et al., 2018), it is no doubt that STING mediates CD8+ T cells. This evidence concerns the gene STING1 and neoplasm.